Beta Bionics是一家糖尿病技术公司,接受混合分析师评级,但看到内幕购买,交易额接近20美元。 Beta Bionics, a diabetes tech firm, receives mixed analyst ratings but sees insider buys, trading near $20.

Beta Bionics是一家开发糖尿病解决方案的公司, 获得了混合分析师的评分, 包括“优异”与“中立”, 平均目标价格为24.83美元, Beta Bionics, a company developing diabetes solutions, has garnered mixed analyst ratings, including "outperform" and "neutral," with an average target price of $24.83 and a "Moderate Buy" consensus. 该公司的股票以19.99美元开放,主要股东和内幕人士购买了大量股份。 The company's stock, which opened at $19.99, has seen significant share purchases by major shareholders and insiders. Beta Bionics 成立于2015年,总部设在加利福尼亚州Irvine。 Beta Bionics, founded in 2015, is based in Irvine, CA.